NEW YORK, Jan 23, 2026, 05:35 EST — Premarket.
- After soaring 152% on Thursday, SXTP slipped nearly 10% in premarket trading.
- 60 Degrees Pharma announced a Runway Health partnership that will launch a telehealth channel for its malaria pill ARAKODA on April 2.
- This week, the company executed a 1-for-4 reverse split to comply with Nasdaq’s minimum bid-price requirement.
Shares of 60 Degrees Pharmaceuticals slipped 9.9% to $4.54 in premarket action on Friday, following a wild session the day before where the stock soared 152% to close at $5.04. Thursday saw the share price swing between $4.40 and $8.62, with trading volume hitting roughly 196 million shares.
The move comes after the company revealed on Thursday its new partnership with Runway Health to expand distribution of its malaria-prevention drug ARAKODA via a travel medicine telehealth platform. The rollout will begin April 2, according to the company.
Why it matters now: the deal came just days after 60 Degrees pulled off a reverse stock split — a tactic to reduce the number of shares and boost the price per share — aimed at keeping its Nasdaq listing. According to an 8-K filing, the company’s 1-for-4 reverse split took effect early on Jan. 20, following an amendment to its Delaware charter.
Runway Health offers a platform where qualifying adults can undergo physician-led online consultations before traveling. If prescribed, medications are delivered to their homes prior to departure, the company said. According to the statement, ARAKODA has contraindications, including for patients with glucose-6-phosphate dehydrogenase deficiency and those with a history of psychotic disorders.
ARAKODA, or tafenoquine, is prescribed to prevent malaria—a mosquito-borne disease—in adults. The Centers for Disease Control and Prevention outlines a three-day initial “loading” phase before travel, then weekly doses during time spent in malaria-risk regions, capped by a final dose after leaving. CDC
Thursday’s jump happened on a volume spike traders track closely in lightly traded stocks. According to Investing.com, about 195.6 million shares exchanged hands, compared to a typical 3.3 million average. That kind of volume swings leaves the stock vulnerable to sudden gaps and rapid pullbacks.
The market is set to put the move to the test during regular trading. Premarket pullbacks following a headline-fueled spike often point to profit-taking, but they can also indicate buyers holding off until it’s clearer whether a marketing deal actually leads to prescriptions.
The risk case is clear-cut. A commercial deal doesn’t ensure demand, especially in malaria prevention—a niche market influenced heavily by travel habits, doctor preferences, and who qualifies for treatment. Plus, the stock’s split-adjusted float is relatively small, which can magnify price swings on either side.
Investors have few big dates ahead, but April 2 stands out — that’s when the Runway Health channel is set to launch. Leading up to that, traders will focus on whether SXTP stays above Nasdaq’s $1 minimum bid. They’ll also be looking for any updates from the company on rollout details or initial order numbers.
